Prescription Medicines
Fenorovan Tab. 2/145mg
- Product Category
- Cardiovascular Medicines
- Active Ingredients
- Pitavastatin calcium, fenofibrate
- Appearance
- Pink oval film-coated tablets
- Reimbursement Code
- 648105310
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredients:
Pitavastatin calcium (in-house specification) ······ 2mg
Fenofibrate (EP) ······ 145mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Sodium docusate, sodium lauryl sulfate, microcrystalline cellulose, white sugar, butylated hydroxyanisole, magnesium stearate, Opadry AMBⅡ 88A640008 pink, low-substituted hydroxypropyl cellulose, colloidal silicon oxide, crospovidone, magnesium carbonate, hypromellose, D-mannitol
2. Effectiveness
Treatment of mixed dyslipidemia in adult patients at high risk of coronary heart disease (CHD) with pitavastatin 2 mg monotherapy, with adequate control of LDL-cholesterol levels but high triglyceride levels and low HDL-cholesterol levels.
3. Dosage and dosage
Creatine kinase (CK) levels should be measured before administering this drug. Baseline values can be used as a reference value to determine whether CK levels have increased during treatment with this drug. CK is not measured after strenuous exercise or when there are other potential factors that may cause CK elevation, as it is difficult to interpret CK levels. If the CK level has significantly increased from baseline to more than 5 times the upper limit of normal, it should be measured again after 5 to 7 days to confirm the results. If CK levels have significantly increased beyond 5 times the upper limit of normal from baseline after 5 to 7 days, treatment with this drug should not be initiated.
Regular monitoring of CK levels is recommended every 3 months for the first 12 months of treatment with this drug, and periodically thereafter. Patients starting treatment with this drug or increasing the statin dose should be informed of the risk of myopathy, and patients should be advised to immediately consult a doctor if they experience unexplained muscle pain, tenderness, muscle weakness, or muscle cramps while taking this drug. Also, in these cases, CK levels should be measured, and if CK levels increase significantly (more than 5 times the upper limit of normal), administration of this drug should be discontinued. Regardless of the CK level, discontinuation of administration should be made considering whether muscle symptoms are severe and whether daily discomfort is caused. If a patient is suspected of having a genetic muscle disease, re-administration of this drug is not recommended.
Before administering this drug, the levels of transaminases (AST, ALT) should be monitored. Monitor them every 3 months for the first 12 months and periodically thereafter. Caution should be exercised in patients with elevated transaminase levels, and treatment with this drug should be discontinued if AST, SGOT, ALT, or SGPT levels increase by more than 3 times the upper limit of normal.
It is recommended that creatinine clearance be systematically evaluated by measuring creatinine clearance every 3 months for the first 12 months after administration of this drug, and then periodically monitored thereafter. If creatinine levels exceed 50% of the upper limit of normal, treatment with this drug should be discontinued.
Secondary causes of hyperlipidemia, such as patients with uncontrolled type 2 diabetes, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, and alcoholism, should be appropriately treated before administering this drug. Patients must follow a standard cholesterol-lowering diet before starting treatment and must continue this during treatment.
The recommended dosage is to take 1 tablet once a day, regardless of meal.
Serum lipid levels (total cholesterol (TC), LDL-C, and triglycerides (TG)) should be monitored in response to treatment.
Since the bioequivalence of this drug has not been established when compared to existing single drug combination administration, patients taking pitavastatin and fenofibrate in combination should not switch to this drug.
Patients with renal impairment: This drug is not administered to patients with moderate to severe renal impairment whose estimated glomerular filtration rate is less than 60 mL/min/1.73 m2.
4. How to save
Airtight container, stored at room temperature (1~30℃)
5. Packaging unit
30 tablets/bottle
6. Period of use
18 months from date of manufacture
- Active ingredients:
Pitavastatin calcium (in-house specification) ······ 2mg
Fenofibrate (EP) ······ 145mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Sodium docusate, sodium lauryl sulfate, microcrystalline cellulose, white sugar, butylated hydroxyanisole, magnesium stearate, Opadry AMBⅡ 88A640008 pink, low-substituted hydroxypropyl cellulose, colloidal silicon oxide, crospovidone, magnesium carbonate, hypromellose, D-mannitol
2. Effectiveness
Treatment of mixed dyslipidemia in adult patients at high risk of coronary heart disease (CHD) with pitavastatin 2 mg monotherapy, with adequate control of LDL-cholesterol levels but high triglyceride levels and low HDL-cholesterol levels.
3. Dosage and dosage
Creatine kinase (CK) levels should be measured before administering this drug. Baseline values can be used as a reference value to determine whether CK levels have increased during treatment with this drug. CK is not measured after strenuous exercise or when there are other potential factors that may cause CK elevation, as it is difficult to interpret CK levels. If the CK level has significantly increased from baseline to more than 5 times the upper limit of normal, it should be measured again after 5 to 7 days to confirm the results. If CK levels have significantly increased beyond 5 times the upper limit of normal from baseline after 5 to 7 days, treatment with this drug should not be initiated.
Regular monitoring of CK levels is recommended every 3 months for the first 12 months of treatment with this drug, and periodically thereafter. Patients starting treatment with this drug or increasing the statin dose should be informed of the risk of myopathy, and patients should be advised to immediately consult a doctor if they experience unexplained muscle pain, tenderness, muscle weakness, or muscle cramps while taking this drug. Also, in these cases, CK levels should be measured, and if CK levels increase significantly (more than 5 times the upper limit of normal), administration of this drug should be discontinued. Regardless of the CK level, discontinuation of administration should be made considering whether muscle symptoms are severe and whether daily discomfort is caused. If a patient is suspected of having a genetic muscle disease, re-administration of this drug is not recommended.
Before administering this drug, the levels of transaminases (AST, ALT) should be monitored. Monitor them every 3 months for the first 12 months and periodically thereafter. Caution should be exercised in patients with elevated transaminase levels, and treatment with this drug should be discontinued if AST, SGOT, ALT, or SGPT levels increase by more than 3 times the upper limit of normal.
It is recommended that creatinine clearance be systematically evaluated by measuring creatinine clearance every 3 months for the first 12 months after administration of this drug, and then periodically monitored thereafter. If creatinine levels exceed 50% of the upper limit of normal, treatment with this drug should be discontinued.
Secondary causes of hyperlipidemia, such as patients with uncontrolled type 2 diabetes, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, and alcoholism, should be appropriately treated before administering this drug. Patients must follow a standard cholesterol-lowering diet before starting treatment and must continue this during treatment.
The recommended dosage is to take 1 tablet once a day, regardless of meal.
Serum lipid levels (total cholesterol (TC), LDL-C, and triglycerides (TG)) should be monitored in response to treatment.
Since the bioequivalence of this drug has not been established when compared to existing single drug combination administration, patients taking pitavastatin and fenofibrate in combination should not switch to this drug.
Patients with renal impairment: This drug is not administered to patients with moderate to severe renal impairment whose estimated glomerular filtration rate is less than 60 mL/min/1.73 m2.
4. How to save
Airtight container, stored at room temperature (1~30℃)
5. Packaging unit
30 tablets/bottle
6. Period of use
18 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Fenorovan Tab. 2/145mg | Precautions for use | 2026.04.28 | PDF0029_202503209_Fenorovan tablet 2/145mg_Precautions for use.pdf |